2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP01.08

PP01.08 - Martin Filipits

Pdf Summary

The research study led by Martin Filipits and colleagues from the Center for Cancer Research at the Medical University of Vienna investigates the clinical relevance of CEACAM5 protein expression in resected lung adenocarcinomas. CEACAM5 is a protein targeted by the antibody drug conjugate tusamitamab ravtansine, evaluated in the CARMEN-LC03 Phase III trial as a monotherapy for previously treated patients with metastatic non-squamous non-small cell lung cancer (NSCLC). The trial failed to meet its primary endpoint of improving progression-free survival, leading to the discontinuation of the drug's development for NSCLC.<br /><br />The study examines the prognostic value of CEACAM5 expression in completely resected lung adenocarcinoma. A total of 161 NSCLC patient specimens were analyzed for CEACAM5 protein expression using immunohistochemistry. The samples were tested with the CB30 antibody, and a threshold of 50% positive tumor cells at any staining intensity was set.<br /><br />The results revealed CEACAM5 immunostaining in 82% of the evaluable tumor samples. However, the presence of CEACAM5 was not significantly correlated with various clinicopathological features like age, gender, tumor stage, mutation status, or patient survival outcomes. Specifically, CEACAM5 expression did not associate with recurrence-free survival or overall survival, as indicated by the hazard ratios and confidence intervals.<br /><br />In conclusion, CEACAM5 expression lacks clinical relevance in the assessed cohort of patients with completely resected lung adenocarcinoma, as it does not impact survival outcomes or correlate with other clinical features.

Keywords

CEACAM5

lung adenocarcinoma

tusamitamab ravtansine

CARMEN-LC03 trial

NSCLC

progression-free survival

immunohistochemistry

prognostic value

clinical relevance

Medical University of Vienna